Brief: Corcept Resubmits New Drug Application For Relacorilant As A Treatment For Patients With Cushing’s Syndrome

Corcept Therapeutics Incorporated

17/06/2026 21:29

    June 17 (Reuters) - Corcept Therapeutics Inc  CORT.O :
    * CORCEPT RESUBMITS NEW DRUG APPLICATION FOR RELACORILANT AS
A TREATMENT FOR PATIENTS WITH CUSHING’S SYNDROME
    * CORCEPT THERAPEUTICS - RESUBMISSION INCLUDES ADDITIONAL
ANALYSES; EXPECTS SIX-MONTH FDA REVIEW

Source text:  ID:nBw77ZWHxa 
Further company coverage:  CORT.O 

 ((Reuters.Briefs@thomsonreuters.com;))